Median PFS and OS for IGHV and FISH of all studies included in this analysis
| No. . | Reference . | n . | Median age (y) . | Males (%) . | Rai/Binet stage (%) . | Progression-free survival (y) . | Overall survival (y) . | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IGHV median* . | FISH median* . | IGHV median* . | FISH median* . | ||||||||||||||||||
| 0 or A . | I/II or B . | III/IV or C . | Mutated . | Unmutated . | 13q– . | NL . | +12 . | 11q– . | 17p– . | Mutated . | Uunmutated . | 13q– . | NL . | +12 . | 11q– . | 17p- . | |||||
| IGHV only | |||||||||||||||||||||
| 1 | 6 | 84 | 63 | 58 | 74 | 11 | 15 | — | — | 24.5 | 9.7 | ||||||||||
| 2 | 5 | 47 | 63 | 67 | 37 | 58 | 5 | — | — | — | 9 | ||||||||||
| 3 | 8 | 307 | 52 | 65 | — | — | — | — | — | — | — | ||||||||||
| 4 | 19 | 303 | 63 | 54 | 34 | 62 | 2 | 10 y: 41% | 10 y: 9% | 10 y: 87% | 10 y: 43% | ||||||||||
| 5 | 10 | 262 | 65 | 61 | 100 | 0 | 0 | 3 y: 93% | 3 y: 66% | — | — | ||||||||||
| 6 | 11 | 337 | 64 | 60 | 71 | 29 | NR | 2 | NR | 7 | |||||||||||
| 7 | 12 | 224 | 63 | 68 | 77 | 23 | 18.9 | 2.5 | 17.9 | 9.8 | |||||||||||
| FISH only | |||||||||||||||||||||
| 8 | 7 | 325 | 62 | 61 | 19 | 60 | 20 | 7.7 | 4.1 | 2.7 | 1.1 | 0.7 | 11 | 9.3 | 9.5 | 6.6 | 2.7 | ||||
| 9 | 13 | 231 | 68 | 63 | 71 | 27 | 2 | — | — | — | — | — | — | — | — | — | — | ||||
| Both IGHV and FISH (OS only) | |||||||||||||||||||||
| 10 | 14 | 325 | 62 | 61 | 20 | 60 | 20 | — | 7.5 | — | — | — | 2.5 | 5.8 | |||||||
| 11 | 15 | 205 | 62 | 58 | 82 | 10 | 7 | 25.8 | 10 | 17.5 | 24.4 | 10.2 | 9.7 | 3.9 | |||||||
| 12 | 16 | 1948 | 60 | 68 | 21 | 56 | 23 | 5 y: 89% | 5 y: 71% | 5 y: 85% | 5 y: 87% | 5 y: 83% | 5 y: 75% | 5 y: 34% | |||||||
| Both IGHV and FISH (PFS only) | |||||||||||||||||||||
| 13 | 17 | 351 | 61 | 61 | 80 | 20 | 11.8 | 4 | 12 | 5 | 5 | 4 | 3 | ||||||||
| 14 | 18 | 930 | 59 | 61 | 87 | 13 | — | — | 5 | 4 | 4 | 3 | 1 | ||||||||
| 15 | 19 | 384 | 61 | 58 | 100 | 0 | 0 | — | 4 | — | — | — | — | 4 | |||||||
| 16 | 20 | 3490 | 65 | 63 | 77 | 23 | — | 3.5 | 12 | — | 4 | 3 | — | ||||||||
| Both IGHV and FISH (PFS and OS) | |||||||||||||||||||||
| 17 | 21 | 706 | 66 | 57 | 76 | 24 | 10.5 | 2 | 9 | 1 | NR | 8 | 20.5 | 6.8 | |||||||
| 18 | 22 | 482 | 67 | 65 | — | — | — | 9.2 | 1.5 | 12 | 6.6 | NR | 1 | 1.8 | 5 y: 88% | 5 y: 81% | NR | NR | NR | NR | 2.5 |
| 19 | 23 | 2487 | 64 | 68 | 52 | 39 | 6 | 11 | 2.8 | NR | 8.7 | 5.4 | 2.4 | 5.2 | NR | 9.7 | NR | NR | 10.9 | 8.4 | 7.6 |
| 20 | 24 | 252 | 64 | 63 | 79 | 16 | 5 | NR | 1.1 | NR | NR | 1.5 | 0.5 | 0.1 | NR | 7 | NR | NR | 7 | 7.6 | 4 |
| 21 | 25 | 255 | 61 | 64 | 95 | 5 | NR | 5 | — | — | — | 4 | 2.6 | — | 3.2 | — | — | — | 3.3 | 5 | |
| 22 | 26 | 1154 | 66 | — | 100 | 0 | 0 | NR | 5 | 22 | 3.6 | 23 | 13 | 23 | 13 | ||||||
| 23 | 27 | 620 | 65 | 60 | 48 | 44 | 8 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| 24 | 28 | 292 | 66% >60 y | 55 | 72 | 28 | 3 y: 58% | 3 y: 23% | 3 y: 49% | 3 y: 37% | 3 y: 28% | 3 y: 21% | 3 y: 24% | 10 y: 75% | 10 y: 41% | 10 y: 93% | 10 y: NR | 10 y: 72% | 10 y: 67% | 10 y: 0% | |
| 25 | 29 | 265 | 64 | 64 | 78 | 22 | NR | 1 | NR | NR | 2 | 1 | <1 | NR | 7 | NR | NR | 10 | 9 | 4 | |
| 26 | 30 | 311 | 66 | 61 | 78 | 15 | 6 | NR | 2 | 5.2 | 1.5 | — | — | — | — | — | — | — | |||
| 27 | 31 | 1274 | 66 | 55 | 80 | 20 | — | — | NR | 8 | 8 | — | — | — | — | 5 y: 84% | 5 y: 78% | 5 y: 63% | 5 y: 54% | 5 y: 48% | |
| 28 | 32 | 949 | 65 | 58 | 57 | 33 | 10 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| 29 | 33 | 468 | 53% >60 y | 59 | 100 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| 30 | 34 | 288 | — | — | 95 | 5 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| 31 | 35 | 1160 | 65 | 65 | — | — | — | — | — | 9.1 | 8.4 | 4.2 | 2.3 | 3.7 | — | — | 7.5 | 7.5 | 7.5 | 5.7 | 4.2 |
| No. . | Reference . | n . | Median age (y) . | Males (%) . | Rai/Binet stage (%) . | Progression-free survival (y) . | Overall survival (y) . | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IGHV median* . | FISH median* . | IGHV median* . | FISH median* . | ||||||||||||||||||
| 0 or A . | I/II or B . | III/IV or C . | Mutated . | Unmutated . | 13q– . | NL . | +12 . | 11q– . | 17p– . | Mutated . | Uunmutated . | 13q– . | NL . | +12 . | 11q– . | 17p- . | |||||
| IGHV only | |||||||||||||||||||||
| 1 | 6 | 84 | 63 | 58 | 74 | 11 | 15 | — | — | 24.5 | 9.7 | ||||||||||
| 2 | 5 | 47 | 63 | 67 | 37 | 58 | 5 | — | — | — | 9 | ||||||||||
| 3 | 8 | 307 | 52 | 65 | — | — | — | — | — | — | — | ||||||||||
| 4 | 19 | 303 | 63 | 54 | 34 | 62 | 2 | 10 y: 41% | 10 y: 9% | 10 y: 87% | 10 y: 43% | ||||||||||
| 5 | 10 | 262 | 65 | 61 | 100 | 0 | 0 | 3 y: 93% | 3 y: 66% | — | — | ||||||||||
| 6 | 11 | 337 | 64 | 60 | 71 | 29 | NR | 2 | NR | 7 | |||||||||||
| 7 | 12 | 224 | 63 | 68 | 77 | 23 | 18.9 | 2.5 | 17.9 | 9.8 | |||||||||||
| FISH only | |||||||||||||||||||||
| 8 | 7 | 325 | 62 | 61 | 19 | 60 | 20 | 7.7 | 4.1 | 2.7 | 1.1 | 0.7 | 11 | 9.3 | 9.5 | 6.6 | 2.7 | ||||
| 9 | 13 | 231 | 68 | 63 | 71 | 27 | 2 | — | — | — | — | — | — | — | — | — | — | ||||
| Both IGHV and FISH (OS only) | |||||||||||||||||||||
| 10 | 14 | 325 | 62 | 61 | 20 | 60 | 20 | — | 7.5 | — | — | — | 2.5 | 5.8 | |||||||
| 11 | 15 | 205 | 62 | 58 | 82 | 10 | 7 | 25.8 | 10 | 17.5 | 24.4 | 10.2 | 9.7 | 3.9 | |||||||
| 12 | 16 | 1948 | 60 | 68 | 21 | 56 | 23 | 5 y: 89% | 5 y: 71% | 5 y: 85% | 5 y: 87% | 5 y: 83% | 5 y: 75% | 5 y: 34% | |||||||
| Both IGHV and FISH (PFS only) | |||||||||||||||||||||
| 13 | 17 | 351 | 61 | 61 | 80 | 20 | 11.8 | 4 | 12 | 5 | 5 | 4 | 3 | ||||||||
| 14 | 18 | 930 | 59 | 61 | 87 | 13 | — | — | 5 | 4 | 4 | 3 | 1 | ||||||||
| 15 | 19 | 384 | 61 | 58 | 100 | 0 | 0 | — | 4 | — | — | — | — | 4 | |||||||
| 16 | 20 | 3490 | 65 | 63 | 77 | 23 | — | 3.5 | 12 | — | 4 | 3 | — | ||||||||
| Both IGHV and FISH (PFS and OS) | |||||||||||||||||||||
| 17 | 21 | 706 | 66 | 57 | 76 | 24 | 10.5 | 2 | 9 | 1 | NR | 8 | 20.5 | 6.8 | |||||||
| 18 | 22 | 482 | 67 | 65 | — | — | — | 9.2 | 1.5 | 12 | 6.6 | NR | 1 | 1.8 | 5 y: 88% | 5 y: 81% | NR | NR | NR | NR | 2.5 |
| 19 | 23 | 2487 | 64 | 68 | 52 | 39 | 6 | 11 | 2.8 | NR | 8.7 | 5.4 | 2.4 | 5.2 | NR | 9.7 | NR | NR | 10.9 | 8.4 | 7.6 |
| 20 | 24 | 252 | 64 | 63 | 79 | 16 | 5 | NR | 1.1 | NR | NR | 1.5 | 0.5 | 0.1 | NR | 7 | NR | NR | 7 | 7.6 | 4 |
| 21 | 25 | 255 | 61 | 64 | 95 | 5 | NR | 5 | — | — | — | 4 | 2.6 | — | 3.2 | — | — | — | 3.3 | 5 | |
| 22 | 26 | 1154 | 66 | — | 100 | 0 | 0 | NR | 5 | 22 | 3.6 | 23 | 13 | 23 | 13 | ||||||
| 23 | 27 | 620 | 65 | 60 | 48 | 44 | 8 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| 24 | 28 | 292 | 66% >60 y | 55 | 72 | 28 | 3 y: 58% | 3 y: 23% | 3 y: 49% | 3 y: 37% | 3 y: 28% | 3 y: 21% | 3 y: 24% | 10 y: 75% | 10 y: 41% | 10 y: 93% | 10 y: NR | 10 y: 72% | 10 y: 67% | 10 y: 0% | |
| 25 | 29 | 265 | 64 | 64 | 78 | 22 | NR | 1 | NR | NR | 2 | 1 | <1 | NR | 7 | NR | NR | 10 | 9 | 4 | |
| 26 | 30 | 311 | 66 | 61 | 78 | 15 | 6 | NR | 2 | 5.2 | 1.5 | — | — | — | — | — | — | — | |||
| 27 | 31 | 1274 | 66 | 55 | 80 | 20 | — | — | NR | 8 | 8 | — | — | — | — | 5 y: 84% | 5 y: 78% | 5 y: 63% | 5 y: 54% | 5 y: 48% | |
| 28 | 32 | 949 | 65 | 58 | 57 | 33 | 10 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| 29 | 33 | 468 | 53% >60 y | 59 | 100 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| 30 | 34 | 288 | — | — | 95 | 5 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| 31 | 35 | 1160 | 65 | 65 | — | — | — | — | — | 9.1 | 8.4 | 4.2 | 2.3 | 3.7 | — | — | 7.5 | 7.5 | 7.5 | 5.7 | 4.2 |
FISH, fluorescence in situ hybridization; IGHV: immunoglobulin heavy-chain variable region gene mutation status; NR, not reached; OS, overall survival; PFS: progression-free survival.
In studies where the median was not reported, outcomes at specific time points (e.g., 3 y PFS or 10 y OS, when available) were included